EPISODE · Jun 10, 2024 · 29 MIN
Ep. 235 - Psychedelic Setback, FDA's Platform Play & ASCO Innovations
from BioCentury This Week · host BioCentury
A snub by an FDA advisory committee for an MDMA-psychotherapy combination is unlikely to read through to other psychedelic therapies in the pipeline. On the BioCentury This Week podcast, BioCentury’s editors discuss the shortcomings of the Lykos Therapeutics product’s clinical development program and why other psychedelics likely won’t face the same hurdles. The editors also assess FDA’s new platform technology designation and the first-in-human clinical trials described at this year’s American Society of Clinical Oncology (ASCO) meeting. This week’s podcast is sponsored by Nxera Pharma.View full story: https://www.biocentury.com/article/65263900:01 - Sponsor Message: Nxera Pharma01:41 - Psychedelic Setback12:38 - FDA's Platform Play21:39 - ASCO InnovationsReach us by sending a text
What this episode covers
A snub by an FDA advisory committee for an MDMA-psychotherapy combination is unlikely to read through to other psychedelic therapies in the pipeline. On the BioCentury This Week podcast, BioCentury’s editors discuss the shortcomings of the Lykos Therapeutics product’s clinical development program and why other psychedelics likely won’t face the same hurdles. The editors also assess FDA’s new platform technology designation and the first-in-human clinical trials described at this year’s Americ...
NOW PLAYING
Ep. 235 - Psychedelic Setback, FDA's Platform Play & ASCO Innovations
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 3, 2026 ·44m
Feb 21, 2026 ·30m
Jan 2, 2026 ·47m